

PROPOSED DIRECTORS AGM 2021



CARL BORREBAECK
(born in 1948). Chairman since 2015, director since 2010.

Education and experience:

Professor of immunotechnology, DSc major in molecular immunology, MSc in chemical engineering, MSc in life science.

Carl Borrebaeck is a professor at the Department of Immunotechnology and program director of the CREATE translational cancer research center at Lund University. He is an entrepreneur and founded SenzaGen AB and several other life science companies, including Immunovia AB and Biolnvent International AB. He is also a founding mentor for the Nordic Mentor Network for Entrepreneurship (NOME), a member of the Royal Swedish Academy of Engineering Sciences (IVA) and a former vice-chancellor at Lund University. Carl has won a number of awards for his entrepreneurship and groundbreaking research, including AkzoNobel's Science Prize in 2009 and the Biotech Builder Award in 2017.

Other significant appointments:

Board chairman of Immunovia AB, PainDrainer AB and CB Ocean Capital AB. Board director at Alligator Bioscience AB and Scandion A/S.

Shareholding:

1,690,000 shares.

Independence:

Not independent of major shareholders but independent of the Company and Management.



LAURA CHIRICA
(born in 1968). Director since 2017.

Education and experience:

PhD in biochemistry, MSc in biochemistry and BSc in biotechnology.

Laura Chirica serves as Chief Commercial Officer at Immunovia AB and has around 20 years of experience from commercial positions in both startups and multinationals from the life sciences and diagnostics industries. Her previous positions include VP Sales and Marketing at Euro Diagnostica AB, director at Purification Technologies Europe Sartorius Stedim, Global Marketing Director at Dako A/S, and Global Marketing Program Manager at GE Healthcare.

Other significant appointments: -

Shareholding:

0.

Independence:

Independent of the Company, Management and major shareholders.



ANKI MALMBORG HAGER
(born in 1965). Director since 2019.

Education and experience:

PhD in immunotechnology, MSc in chemical engineering, Pharma MBA.

Anki Malmberg Hager has extensive experience of starting life science companies originating from Lund university research and is currently CEO of PainDrainer AB. Anki served as CEO of SenzaGen from 2014 to 2019. Her past experience includes CEO of Cantargia AB, XImmune AB and Diaprost AB, and before that, Investment Director at LU Bioscience AB and VP Business Development at Alligator Bioscience AB.

Other significant appointments:

CEO of PainDrainer AB. Board director at Avena Partners AB and DiaProst AB.

Shareholding:

383,000 shares.

Independence:

Not independent of the Company and Management. Independent of major shareholders.



IAN KIMBER
(born in 1950). Director since 2015.

Education and experience:

Emeritus Professor of Toxicology, PhD and MSc in immunology, BSc in biology.

Ian Kimber serves as Emeritus Professor of Toxicology at the University of Manchester. He has extensive experience from academia, the pharmaceutical, biopharmaceutical and agrochemical industries, and as an independent consultant. Ian has won several awards for his distinguished scientific work and received the OBE in the Queen's Birthday Honours List in 2011. He serves on many expert committees and scientific advisory groups in the UK and internationally.

Other significant appointments:

Emeritus Professor of Toxicology at the University of Manchester.

Shareholding:

1,500 shares.

Independence:

Independent of the Company, Management and major shareholders.



PETER NÄHLSTEDT
(born in 1974). Director since 2018.

Education and experience: MSc in chemical engineering, BSc in business administration.

Peter Nählstedt has around 20 years of management experience in the life sciences and the industrial sector, and he currently runs his own consulting business in the fields of business development and management. Peter has broad international experience and previously served as CEO of Probi. He also held other management positions in strategy, marketing and sales with GE Healthcare Life Science and at Trelleborg Marine Systems where he was responsible for operations in Europe, South America and North Africa.

Other significant appointments:

Board chairman at Super Synbiotics AB and DoubleGood AB. Board director at Bio-works AB.

Shareholding:

1,622 shares and 25,000 stock options.

Independence:

Independent of the Company, Management and major shareholders.



PAUL YIANNI
(born in 1959). Director since 2020.

Education and experience: PhD in chemistry.

Paul Yianni runs his own consulting business with a focus on business development, strategy and business coaching. Paul has over 30 years of management experience from the chemicals industry, and he has broad international experience from various technical and commercial functions, including at Dow Corning and Shell Chemicals. His previous positions include CEO of Spolchemie in Czechia and head of M&A at DIC Europe in Germany.

Other significant appointments: -.

Shareholding:

0.

Independence:

Independent of the Company, Management and major shareholders.



PAULA ZEILON
(born in 1962). Director since 2020.

Education and experience:

MSc in chemical engineering, BSc in business administration.

Paula Zeilon has 30 years of management experience from the life science industry and runs her own consulting business in the fields of business development and management focusing on the commercialization of new products on international markets. Her past experience includes CEO of Life Science Foresight Institute, CEO of Alligator Biosciences AB, Director Marketing at Dako A/S, Director Marketing at Biotage AB, and management positions with Pharmacia Biotech (now Cytiva).

Other significant appointments: -.

Shareholding: 0.

Independence:

Independent of the Company, Management and major shareholders.